Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT04724226
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab; Apatinib — DRUG
    Cryoablation Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD

Study Details

The purpose of this study is to evaluate the efficacy and safety of cryoablation combined with pd-1 antibody immunotherapy (Camrelizumab) and anti-angiogenesis therapy (Apatinib) in patients with advanced hepatocellular carcinoma (HCC).

Key Dates

Start date
Sep 1, 2021
Status verified
Aug 2021
Primary completion
Aug 31, 2023
Completion
Aug 31, 2024

Study Design

Enrollment
34 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: C-couple
    Camrelizumab and Apatinib after Cryoablation

Primary Outcome Measure

Objective response rate (ORR) by RECIST 1.1 and mRECIST [ Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to 2 years) ]

Central Contacts

Related Studies